Skip to Content
Merck
CN

699855P

Avanti

3D-(6-acyl) PHAD™

Avanti Research™ - A Croda Brand

Synonym(s):

Monophosphoryl Hexa-acyl Lipid A, 3-Deacyl (Synthetic)

Sign In to View Organizational & Contract Pricing.

Select a Size

About This Item

Empirical Formula (Hill Notation):
C96H184N3O21P
CAS Number:
252042-59-4
Molecular Weight:
1747.47
UNSPSC Code:
12352211
NACRES:
NA.25

Key Documents

View All Documentation
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Product Name

3D-(6-acyl) PHAD™, Avanti Research™ - A Croda Brand

InChI

1S/C96H181N2O21P.H3N/c1-7-13-19-25-31-37-40-46-52-58-64-70-85(102)113-78(67-61-55-49-43-34-28-22-16-10-4)73-83(100)97-89-92(107)91(106)82(116-95(89)108)77-112-96-90(98-84(101)74-79(68-62-56-50-44-35-29-23-17-11-5)114-86(103)71-65-59-53-47-41-38-32-26-20-1

InChI key

BKGJOWVNLQLVQX-ZLHZNJIMSA-N

SMILES string

O[C@H]([C@@H](CO[C@@H]([C@@H]1NC(C[C@H](OC(CCCCCCCCCCCCC)=O)CCCCCCCCCCC)=O)O[C@H](CO)[C@@H](OP([O-])(O)=O)[C@@H]1OC(C[C@H](OC(CCCCCCCCCCCCC)=O)CCCCCCCCCCC)=O)O[C@H](O)[C@@H]2NC(C[C@H](OC(CCCCCCCCCCCCC)=O)CCCCCCCCCCC)=O)[C@@H]2O.[NH4+]

assay

>99% (HPLC)

form

powder

packaging

pkg of 1 × 1 mg (699855P-1mg)
pkg of 1 × 10 mg (699855P-10MG)
pkg of 1 × 10 mg (699855P-25MG)
pkg of 1 × 5 mg (699855P-5mg)

manufacturer/tradename

Avanti Research™ - A Croda Brand

application(s)

vaccine development

shipped in

dry ice

storage temp.

−20°C

Application

3D-(6-acyl) PHAD™ has been used:
  • as a synthetic adjuvant in human papillomavirus (HPV) and virus-like particles (VLPs)-based HPV vaccine preparations
  • as a component of liposomes for immunizing mice with P. falciparum (Pfs25) malaria transmission-blocking vaccine antigen candidate
  • in liposome preparation for the generation of army liposome formulation (ALF) for human immunodeficiency (HIV) gp140 antigen immunization studies in mice

General description

Vaccination is well-accepted as an effective method to prevent infections by mounting pathogen-specific immune responses prior to the infection. Usually, immunization with vaccine antigens alone is not able to induce robust or long-lasting immune responses — resulting in failure of protective immunity against infections. Thus, adjuvants are required to enhance cellular or humoral immune responses upon immunization. Because vaccine adjuvants using Lipid A have proven to be safe and effective in inducing Th-1 type immune responses to heterologous proteins in animal and human vaccines, Avanti developed Phosphorylated HexaAcyl Disaccharide (PHAD™), the first fully synthetic monophosphoryl Lipid A available for use as an adjuvant in human vaccines.

Other Notes

For R&D use only. Not for drug, household, or other uses.

Packaging

2 mL Amber Glass Crimp Cap Vial (699855P-1mg)
2 mL Amber Glass Crimp Cap Vial (699855P-5mg)
5 mL Amber Glass Screw Cap Vial (699855P-10MG);5 mL Amber Glass Screw Cap Vial (699855P-25MG)

Legal Information

Avanti Research is a trademark of Avanti Polar Lipids, LLC
PHAD is a trademark of Avanti Polar Lipids, LLC

Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

No data available

flash_point_c

No data available

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.

If you need assistance, please contact Customer Support

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Immune response to antigen adsorbed to aluminum hydroxide particles: Effects of co-adsorption of ALF or ALFQ adjuvant to the aluminum-antigen complex
Beck Z, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society, 275, 12-19 (2018)
Shuai Shao et al.
Annals of biomedical engineering (2019-12-14)
A vaccine that induces broadly neutralizing antibodies (bnAbs) against the human immunodeficiency virus (HIV) would be instrumental in controlling the disease. The membrane proximal external region (MPER) peptide is an appealing antigen candidate since it is conserved and is the
A malaria vaccine adjuvant based on recombinant antigen binding to liposomes
Huang WC, et al.
Nature Nanotechnology, 13(12), 1174-1181 (2018)
Immunogenicity of HPV and HBV vaccines: adjuvanticity of synthetic analogs of monophosphoryl lipid A combined with aluminum hydroxide
Taleghani N, et al.
Acta Pathologica, Microbiologica et Immunological Scandinavica, 127(3), 150-157 (2019)

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service